The Rapamycin Longevity Lab is a cutting-edge research organization focused on advancing the use of mTOR inhibitors as the core component in longevity combinational therapies. The lab is founded by Krister Kauppi and the aim is to develop combinational therapies that not only slow down aging but also eventually solve aging altogether. By leveraging mTOR inhibitor’s potential and combining it with other interventions, the lab seeks to extend lifespan and improve healthspan in both animal models and humans.
Krister Kauppi is the founder of the Rapamycin Longevity Lab. His vision is to take mTOR inhibition to the next level by using it as a core component when developing combinational therapies in the longevity field. Krister advocates for the importance of combination therapies for addressing aging at its cor rather than just relying on one single intervention.
The Rapamycin Longevity Lab is building expertise in engineering longevity combinational therapies — these therapies combine the next generation of mTOR inhibitors with other longevity interventions to achieve optimal effects in lifespan extension. The lab is positioning itself as a leader in the field of combinational therapies and by that contribute to fill a gap in the current aging research landscape. Through partnerships with companies like Ora Biomedical, Rapamycin Longevity Lab efficiently screens and tests new combinational therapies, with a long-term goal of translating this research into human clinical trials.
Apply to become a Certified Vitalist Organization and align with others dedicated to this mission
CERTIFICATION APPLICATION
